Poison pills remain as Lilly shareholder vote falls short
The proposal garnered support from the owners of 62 percent of Eli Lilly’s outstanding shares. To pass, the proposal needed approval from the owners of 80 percent of Lilly’s shares.
Pharmaceutical
Articles
Endocyte could get $1B from Merck development deal
Endocyte Inc. stock more than doubled in premarket trading after the company entered into an agreement to develop its ovarian cancer treatment with pharmaceutical giant Merck & Co.
New Lilly drug has small sales potential
Eli Lilly and Co.’s newest drug is a boon for Alzheimer’s research but is likely to bring the Indianapolis drugmaker less than $100 million in annual sales—at least initially, according to one of the few analysts to make a forecast.
Express Scripts-Medco deal approved by U.S. regulators
Express Scripts Inc.’s $29.1 billion bid for rival drug benefit manager Medco Health Solutions Inc. won unconditional approval from U.S. antitrust regulators, clearing the way to create the biggest manager of prescription-drug benefits for corporate and government clients.
Lilly receives Europe’s OK for new Byetta use
European regulators have approved an expanded use for the diabetes treatment Byetta, developed by Eli Lilly and Co. and Amylin Pharmaceuticals Inc. The FDA approved the same expanded use last fall.
Lilly to focus on cancer, diabetes in China, CEO says
Indianapolis-based Eli Lilly and Co. will introduce “over a dozen” new products in China in the next five years, focusing on “unmet needs” such as cancer and diabetes, CEO John Lechleiter said this week.
Express Scripts’ Medco deal may be delayed by potential suit
Express Scripts Inc.’s bid to acquire Medco Health Solutions Inc. and create the largest U.S. pharmacy-benefits manager may be delayed by a lawsuit being considered by five states.
Endocyte pulls trigger on European drug submission
Endocyte Inc. will submit its ovarian cancer drug EC145 for European market approval in the third quarter of this year after the European Commission granted it orphan drug status.
FTC asks critics of Express Scripts-Medco deal for ideas
Two pharmacy groups opposing Express Scripts Inc.’s proposed acquisition of Medco Health Solutions Inc. said they were asked by the U.S. Federal Trade Commission to suggest ways to revise the $29.1 billion deal so it wouldn’t harm competition.
FDA removes hurdle in Endocyte’s path to drug approval
Endocyte Inc. can start enrolling patients again in a clinical trial of its experimental cancer drug, the company announced Monday, clearing away a hurdle to getting the drug approved in Europe.
Lilly settles Zyprexa marketing suit for $1.4 billion
Indianapolis-based Lilly pleaded guilty to one violation of the Food, Drug and Cosmetic Act on Thursday and agreed to pay $1.42 billion to settle both that criminal charge as well as civil lawsuits in which it did not admit wrongdoing.
New drugmaker code deprives docs of football, lunch for 2
Doctors can still get free samples of medicines, but not football tickets or lunch for their spouses, under a revised code of conduct drafted by a global drug industry trade group that counts Eli Lilly as a member.
Lilly plans 200 jobs at new $440M Ireland plant
Eli Lilly and Co. plans to invest about $440 million in a new pharmaceutical plant at an existing company site in County Cork in southern Ireland. The facility in Kinsale will require as many as 200 skilled employees when fully operational.
Drugmakers singing same song: 2012 will be tough
For drugmakers, the golden era of the 1990s and early part of the last decade, when they seemed to effortlessly churn out new multibillion-dollar pills for the masses along with double-digit quarterly profit increases, is not even in the rearview mirror any more.
Lilly eying deal with Turkish drug company
Eli Lilly and Co. is among about a half-dozen companies interested in buying a stake in Mustafa Nevzat Ilac Sanayii AS in a deal that may value the Turkish drugmaker at $1 billion, sources say.
Lilly’s ex-partner wins FDA approval for diabetes drug
Amylin Pharmaceuticals Inc. and Alkermes Plc have gained U.S. clearance for Bydureon, a once-weekly diabetes shot. Eli Lilly and Co. co-developed the drug, but ended its partnership with Amylin last year.
Indiana Senate panel backs limits on abortion pill
The Senate health committee voted 5-4 in support of the bill that requires that a doctor examine a woman in person before giving her RU-486, provide written information about the physical risks of abortion and to schedule a follow-up ultrasound.
Deal with Walgreen perplexes Arcadia’s investors
Something doesn’t add up about Arcadia Resources Inc.’s agreement to sell its pharmacy business for a low price of $2 million, according to many of the Indianapolis company’s investors.
Lechleiter bets history will repeat for Lilly
Eli Lilly and Co. CEO John Lechleiter keeps pouring more money into research and development, even as analysts note the payoff of such spending has dropped off 70 percent in the last decade.
Drugmaker plans 234 Terre Haute jobs by 2016
A California-based pharmaceutical company says it expects to hire 234 people by 2016 at a new operation on the site of a former Pfizer Inc. drug plant near Terre Haute.